Publication:
Reproducibility of technetium-99m mercaptoacetyltriglycine clearance in patients with impaired renal function

dc.contributor.authorÖNEŞ, TUNÇ
dc.contributor.authorTUĞLULAR, ZÜBEYDE SERHAN
dc.contributor.authorsErdil, TY; Dede, F; Tuglular, S; Sen, F; Ones, T; Farsakoglu, Z; Inanir, S; Ozener, C; Akoglu, E; Turoglu, T
dc.date.accessioned2022-03-12T17:19:35Z
dc.date.accessioned2026-01-11T16:38:23Z
dc.date.available2022-03-12T17:19:35Z
dc.date.issued2006
dc.description.abstractBackground The aim of this study was to determine the reproducibility of technetium-99m mercaptoacetyltriglycine ((99)mTc-MAG3) clearance in patients with a 99mTc-MAG3 clearance below 100 ml/min/1.73 m(2). Methods Two separate multi-sample clearance studies were performed in 16 patients at a 1 week interval. The clearances were calculated according to the open two-compartment model of Sapirstein et al., accepting the 90, 120 and 180 min samples as the last points of the biexponential curve. The clearance measurements were also performed according to the single-sample methods of Russell et al. and Bubeck using the fitted value at 44 min. Results There was no significant difference between the two clearance measurements for all five samples (P > 0.05). There was a systematic increase in clearance measurements of 8.0 +/- 2.7% from the 180 to 120 min samples and 4.8 +/- 2.0% from the 120 to 90 min samples. Both single-sample methods (Bubeck and Russell et al.) gave more divergent results than multi-sample methods. The mean and standard deviation (%) of the normalized differences between two successive tests were -3.9 +/- 12.6, -2.4 +/- 13.1, -1.9 +/- 14.9, -4.1 +/- 53.5 and -13 +/- 82.1 for 90,120 and 180min samples and the Russell et al. and Bubeck methods, respectively. Conclusion Single-sample methods give very poor reproducibility and accuracy and should not be used in patients with poor renal function. The reproducibility of Tc-99m-MAG3 clearance using the multi-sample method (90 min) in patients with impaired renal function is 12.6%, which is similar to that in patients with good renal function and that obtained with other tubular agents. Whether this level of reproducibility is satisfactory for documenting serial changes in an individual patient with a Tc-99m-MAG3 clearance below 100 ml/min/1.73 m(2) depends on the expectation of the clinician.
dc.identifier.doi10.1097/01.mnm.0000195674.75664.ba
dc.identifier.eissn1473-5628
dc.identifier.issn0143-3636
dc.identifier.pubmed16404234
dc.identifier.urihttps://hdl.handle.net/11424/228128
dc.identifier.wosWOS:000235359500014
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartofNUCLEAR MEDICINE COMMUNICATIONS
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectclearance
dc.subjectimpaired renal function
dc.subjectreproducibility
dc.subjectTc-99m-MAG3
dc.subjectGLOMERULAR-FILTRATION RATE
dc.subjectTECHNETIUM-99M MAG3
dc.subjectSINGLE-INJECTION
dc.subjectTC-99(M)-MAG3 CLEARANCE
dc.subjectNORMAL VOLUNTEERS
dc.subjectPLASMA-CLEARANCE
dc.subjectSAMPLE
dc.subjectRADIONUCLIDES
dc.subjectACCURACY
dc.subjectCHILDREN
dc.titleReproducibility of technetium-99m mercaptoacetyltriglycine clearance in patients with impaired renal function
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage196
oaire.citation.issue2
oaire.citation.startPage191
oaire.citation.titleNUCLEAR MEDICINE COMMUNICATIONS
oaire.citation.volume27

Files